Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price rose 21.9% on Tuesday . The company traded as high as C$0.20 and last traded at C$0.20. Approximately 262,425 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 496,726 shares. The stock had previously closed at C$0.16.
Hemostemix Trading Up 18.8 %
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The firm’s 50-day simple moving average is C$0.20 and its 200 day simple moving average is C$0.12. The firm has a market cap of C$27.69 million, a P/E ratio of -5.54 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- The Significance of Brokerage Rankings in Stock Selection
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
